---
category: news
title: "Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma"
excerpt: "PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADRÂ® artificial intelligence (\"A.I.\") platform"
publishedDateTime: 2020-12-17T12:00:00Z
originalUrl: "https://www.prnewswire.com/news-releases/lantern-pharma-announces-collaboration-with-world-leading-brain-cancer-program-at-johns-hopkins-to-further-develop-lp-184-as-therapy-for-glioblastoma-301194949.html"
webUrl: "https://www.prnewswire.com/news-releases/lantern-pharma-announces-collaboration-with-world-leading-brain-cancer-program-at-johns-hopkins-to-further-develop-lp-184-as-therapy-for-glioblastoma-301194949.html"
type: article
quality: 15
heat: 15
published: false

provider:
  name: PR Newswire
  domain: prnewswire.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg?p=facebook"
    width: 939
    height: 491
    isCached: true

secured: "JUbuOfdPDMMbXNWwvU5HVmd7nPGgrsG56jGBciRZMGy8AiEga+O7EaMgpVP47ulFOPW3YjoX59PLtnsYEJKjIrUDhqjSLgC0AOHYlw5ns7oRuvmJPQdGittbxzVOVtIF51EiZe7e55xCcijDh/0lh1BKX7a2hKFXn4n1r2DdhxT2ssQmstG2e3QF4/MYr1ZRer1J1aTN1jJE3lO8zvloSm1bDMxfB+xm0aa8+Edu8l5pJdkTDX0CRXpVrrWGFBmSmKzmJ/GWz9neiLjqNLSfifJ64i3+AHOy6gGOq0H0vb8BQE//LiOTriFV9qaAdW0woN83zKV9qZonjRW7ioaBHowiKt5cIqfgK2ada/975IY=;BvD9hksIVleEa6muI9RFnA=="
---

